先进的多学科治疗侵袭性胸腺瘤与顺铂、阿霉素、甲基强的松龙。

文章的细节

引用

复制到剪贴板

横井K, Matsuguma H, Nakahara R,近藤T, Kamiyama Y, Mori K, Miyazawa N

先进的多学科治疗侵袭性胸腺瘤与顺铂、阿霉素、甲基强的松龙。

J Thorac 1月杂志。2007;2 (1):73 - 8。doi: 10.1097 / JTO.0b013e31802bafc8。

PubMed ID

17410014 (在PubMed

]

文摘

背景和目标:先进的侵袭性胸腺瘤手术切除和放疗通常不可控的。我们回顾了我们的经验与多学科的方法和评估化疗治疗侵袭性胸腺瘤。患者和方法:连续17例侵袭性胸腺瘤患者治疗的多峰性治疗包括化疗、手术、和/或放射治疗。四个患者III期与上腔静脉疾病入侵,九是IVa期疾病,和四个阶段IVb疾病司长委任。化疗方案由顺铂、阿霉素、甲强龙(营)。在新辅助化疗是管理设置的14个病人和佐剂设置其余三个病人。所有患者手术切除的目的是。在这些治疗,化疗和/或放疗进行。结果:除了一个诱导化疗对患者的14营疗法,和响应率为92.9%。其中7名患者接受手术切除,化疗完全缓解后,和其他人进行了部分缓解。 All three patients treated with surgical resection and then chemotherapy with or without radiotherapy also achieved complete remission. Tumor progression after multimodality therapy occurred in 10 patients. After retreatment, eight of these patients were alive at the time of analysis, with a median survival time after recurrence of 30 months. The 5- and 10-year overall survival rates for all patients were both 80.7%. The major side effect of CAMP therapy was acceptable neutropenia. CONCLUSIONS: CAMP therapy was highly effective for invasive thymomas, and the multimodality therapy containing this chemotherapy brought about good disease control in the majority of patients. We believe that this multidisciplinary treatment with CAMP therapy, surgery, and radiotherapy is a justifiable initial treatment for patients with advanced invasive thymoma. Furthermore, appropriate treatments are essential for the long-term survival of patients with recurrences after multimodality therapy.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

阿霉素